Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (1041-1050 of 1,095) with videos related to

Pageof 110
Sort By:
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Journal of Viral Hepatitis|July 6, 2013
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conferenceA Hatzakis, P Van Damme, K Alcorn, et al.
Journal of Gastroenterology and Hepatology|March 13, 2024
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational studyTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Cancers|January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic FactorsMatteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortalityTomoko Nakanishi, Sara Pigazzini, Frauke Degenhardt, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Pageof 110

Showing results (1041-1050 of 1,095) with videos related to

Sort By:
Pageof 110
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Journal of Viral Hepatitis|July 6, 2013
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conferenceA Hatzakis, P Van Damme, K Alcorn, et al.
Journal of Gastroenterology and Hepatology|March 13, 2024
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational studyTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Cancers|January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic FactorsMatteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortalityTomoko Nakanishi, Sara Pigazzini, Frauke Degenhardt, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Pageof 110